Sana Biotechnology Inc (SANA)
3.19
-0.55
(-14.71%)
USD |
NASDAQ |
Nov 05, 10:23
Sana Biotechnology Total Liabilities (Quarterly): 279.02M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 279.02M |
| March 31, 2024 | 306.24M |
| December 31, 2023 | 277.79M |
| September 30, 2023 | 265.59M |
| June 30, 2023 | 352.12M |
| March 31, 2023 | 318.67M |
| December 31, 2022 | 323.40M |
| September 30, 2022 | 332.08M |
| June 30, 2022 | 331.58M |
| Date | Value |
|---|---|
| March 31, 2022 | 345.96M |
| December 31, 2021 | 400.90M |
| September 30, 2021 | 402.67M |
| June 30, 2021 | 353.94M |
| March 31, 2021 | 422.48M |
| December 31, 2020 | 1.151B |
| September 30, 2020 | 1.079B |
| December 31, 2019 | 557.73M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
265.59M
Minimum
Sep 2023
1.151B
Maximum
Dec 2020
441.21M
Average
345.96M
Median
Mar 2022
Total Liabilities (Quarterly) Benchmarks
| Foghorn Therapeutics Inc | 342.91M |
| Omega Therapeutics Inc | 141.96M |
| Moderna Inc | 3.968B |
| Summit Therapeutics Inc | 64.93M |
| Apellis Pharmaceuticals Inc | 640.16M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 618.67M |
| Shareholders Equity (Quarterly) | 339.65M |